345 related articles for article (PubMed ID: 35663978)
81. Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?
Antolín S; García-Caballero L; Reboredo C; Molina A; Mosquera J; Vázquez-Boquete Á; Gallego R; Santiago MP; Concha Á; Pérez E; Calvo L; García-Caballero T
Virchows Arch; 2021 Oct; 479(4):853-857. PubMed ID: 33934230
[TBL] [Abstract][Full Text] [Related]
82. Neoadjuvant Therapy for HER2-positive Breast Cancer.
Wuerstlein R; Harbeck N
Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
[TBL] [Abstract][Full Text] [Related]
83. Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer.
Quartino AL; Li H; Jin JY; Wada DR; Benyunes MC; McNally V; Viganò L; Nijem I; Lum BL; Garg A
Cancer Chemother Pharmacol; 2017 Feb; 79(2):353-361. PubMed ID: 28074265
[TBL] [Abstract][Full Text] [Related]
84. A 10-Gene Signature for Predicting the Response to Neoadjuvant Trastuzumab Therapy in HER2-Positive Breast Cancer.
Jia L; Ling Y; Li K; Zhang L; Wang Y; Kang H
Clin Breast Cancer; 2021 Dec; 21(6):e654-e664. PubMed ID: 34052107
[TBL] [Abstract][Full Text] [Related]
85. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM; Miles D; Kim SB; Im YH; Im SA; Semiglazov V; Ciruelos E; Schneeweiss A; Loi S; Monturus E; Clark E; Knott A; Restuccia E; Benyunes MC; Cortés J;
Lancet Oncol; 2020 Apr; 21(4):519-530. PubMed ID: 32171426
[TBL] [Abstract][Full Text] [Related]
86. Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.
Singer CF; Tan YY; Fitzal F; Steger GG; Egle D; Reiner A; Rudas M; Moinfar F; Gruber C; Petru E; Bartsch R; Tendl KA; Fuchs D; Seifert M; Exner R; Balic M; Bago-Horvath Z; Filipits M; Gnant M;
Clin Cancer Res; 2017 Jul; 23(14):3676-3683. PubMed ID: 28143867
[No Abstract] [Full Text] [Related]
87. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.
Kogawa T; Fouad TM; Liu DD; Wu J; Shen Y; Masuda H; Fujii T; Chavez-MacGregor M; Alvarez RH; Hortobágyi GN; Valero V; Ueno NT
Oncologist; 2016 Jan; 21(1):21-7. PubMed ID: 26659222
[TBL] [Abstract][Full Text] [Related]
88. Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study.
Stroes CI; Schokker S; Creemers A; Molenaar RJ; Hulshof MCCM; van der Woude SO; Bennink RJ; Mathôt RAA; Krishnadath KK; Punt CJA; Verhoeven RHA; van Oijen MGH; Creemers GJ; Nieuwenhuijzen GAP; van der Sangen MJC; Beerepoot LV; Heisterkamp J; Los M; Slingerland M; Cats A; Hospers GAP; Bijlsma MF; van Berge Henegouwen MI; Meijer SL; van Laarhoven HWM
J Clin Oncol; 2020 Feb; 38(5):462-471. PubMed ID: 31809243
[TBL] [Abstract][Full Text] [Related]
89. Pertuzumab and trastuzumab: the rationale way to synergy.
Richard S; Selle F; Lotz JP; Khalil A; Gligorov J; Soares DG
An Acad Bras Cienc; 2016; 88 Suppl 1():565-77. PubMed ID: 27275646
[TBL] [Abstract][Full Text] [Related]
90. [Relationship between HER2 Gene Amplification and the Therapeutic Effect of Pertuzumab in HER2-Positive Breast Cancer].
Nakamura Y; Takuwa H; Takeuchi M
Gan To Kagaku Ryoho; 2020 Aug; 47(8):1193-1195. PubMed ID: 32829353
[TBL] [Abstract][Full Text] [Related]
91. HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results.
Seo J; Koh J; Lee DW; Kim J; Ryu HS; Lee KH; Kim TY; Im SA
Breast Cancer Res; 2023 Dec; 25(1):154. PubMed ID: 38098054
[TBL] [Abstract][Full Text] [Related]
92. Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes.
Hassett MJ; Li H; Burstein HJ; Punglia RS
Breast Cancer Res Treat; 2020 May; 181(1):43-51. PubMed ID: 32185586
[TBL] [Abstract][Full Text] [Related]
93. Differences between the efficacy of HER2(2+)/FISH-positive and HER2(3+) in breast cancer during dual-target neoadjuvant therapy.
Chen W; Li FX; Lu DL; Jiang J; Li J
Breast; 2023 Oct; 71():69-73. PubMed ID: 37517155
[TBL] [Abstract][Full Text] [Related]
94. Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype.
Force J; Howie LJ; Abbott SE; Bentley R; Marcom PK; Kimmick G; Westbrook K; Sammons SL; Parks M; Topping DL; Emerson R; Broadwater G; Hyslop T; Blackwell KL; Nair SK
Clin Breast Cancer; 2018 Oct; 18(5):410-417. PubMed ID: 29615305
[TBL] [Abstract][Full Text] [Related]
95. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
[TBL] [Abstract][Full Text] [Related]
96. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
[TBL] [Abstract][Full Text] [Related]
97. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
[TBL] [Abstract][Full Text] [Related]
98. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
[TBL] [Abstract][Full Text] [Related]
99. Complete pathological response in patients with HER2 positive breast cancer treated with neoadjuvant therapy in Colombia.
Rodríguez M; González DM; El-Sharkawy F; Castaño M; Madrid J
Biomedica; 2023 Sep; 43(3):396-405. PubMed ID: 37871573
[TBL] [Abstract][Full Text] [Related]
100. Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis.
Fasching PA; Hartkopf AD; Gass P; Häberle L; Akpolat-Basci L; Hein A; Volz B; Taran FA; Nabieva N; Pott B; Overkamp F; Einarson H; Hadji P; Tesch H; Ettl J; Lüftner D; Wallwiener M; Müller V; Janni W; Fehm TN; Schneeweiss A; Untch M; Pott D; Lux MP; Geyer T; Liedtke C; Seeger H; Wetzig S; Hartmann A; Schulz-Wendtland R; Belleville E; Wallwiener D; Beckmann MW; Brucker SY; Kolberg HC
Breast Cancer Res Treat; 2019 Jan; 173(2):319-328. PubMed ID: 30324275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
